ALK-Abelló A/S
ALK-Abelló A/S (AKBLF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
akblf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for ALK-Abelló A/S (AKBLF) measures how much investors pay for each dollar of the company's trailing earnings. AKBLF's current PE ratio of 45.84x is calculated by dividing its stock price of $31.35 by its TTM earnings per share of $5.78. −36.1% discount vs 5Y avg 71.7x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 17 fiscal years · Front-end computedMinQ1 · 25%41.0x
MedianQ3 · 75%690.4x
Max
At 45.84x, AKBLF's current P/E is within its average historical range over the past 17 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
ALK-Abelló A/SYou AKBLF | $6.3B | 45.84x | +66.0% | $5.78 |
 Camurus AB (publ) CAMRF | $3.5B | 49.84x | +80.5% | $12.42 |
 Clicks Group Limited CLCGY | $3.4B | 28.13x | +1.9% | $26.57 |
 COSMOS Pharmaceutical Corporation CSMYF | $3.3B | 16.92x | -38.7% | $390.86 |
 Fielmann AG FLMNY | $4.3B | 18.62x | -32.6% | $0.47 |
 Getinge AB (publ) GNGBF | $5.1B | 24.58x | -11.0% | $8.29 |
 Genscript Biotech Corporation GNNSF | $4.2B | N/A | — | -$0.25 |
Industry Average 5 peers with valid PE | — | 27.62x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 42.58x | $5.39 | -2.6% | |
2024-12-31 FY2024 | 43.72x | $3.68 | +7.4% | |
2023-12-31 FY2023 | 40.71x | $2.20 | -36.4% | |
2022-12-31 FY2022 | 64.00x | $1.52 | -61.8% | |
2021-12-31 FY2021 | 167.65x | $1.00 | -75.7% | |
2020-12-31 FY2020 | 690.41x | $0.11 | — | |
2019-12-31 FY2019 | — | $-0.23 | — | |
2018-12-31 FY2018 | — | $-0.78 | — | |
2017-12-31 FY2017 | — | $-0.80 | — | |
2016-12-31 FY2016 | 33.86x | $1.38 | +37.7% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for ALK-Abelló A/S (AKBLF) measures how much investors pay for each dollar of the company's trailing earnings. AKBLF's current PE ratio of 45.84x is calculated by dividing its stock price of $31.35 by its TTM earnings per share of $5.78.
Frequently asked questions
AKBLF pe ratio · 6 questionsAKBLF's current PE ratio is 45.84x as of 2026-06-09, based on a stock price of $31.35 and TTM EPS of $5.78. Data sourced from Financial Modeling Prep via AKBLF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · ALK-Abelló A/S SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09